Trials / Completed
CompletedNCT04412863
Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218 Alone or in Combination With Pegylated Interferon Alpha-2a
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 84 (actual)
- Sponsor
- Vir Biotechnology, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2 study in which subjects with chronic hepatitis B virus (HBV) infection will receive VIR-2218 alone or in combination with pegylated interferon alfa-2a and will be assessed for safety, tolerability, pharmacokinetics, and antiviral activity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VIR-2218 | VIR-2218 given by subcutaneous injection |
| DRUG | pegylated interferon-alfa 2a | pegylated interferon-alfa 2a given by subcutaneous injection |
Timeline
- Start date
- 2020-07-03
- Primary completion
- 2024-03-25
- Completion
- 2024-03-25
- First posted
- 2020-06-02
- Last updated
- 2026-04-16
- Results posted
- 2026-04-16
Locations
22 sites across 6 countries: Australia, Hong Kong, Malaysia, New Zealand, South Korea, Thailand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04412863. Inclusion in this directory is not an endorsement.